• Small Molecules
    • Services
      • Drug Substance (API)
      • Particle Engineering
      • Drug Product
    • Technologies
      • Highly Potent API (HPAPI)
      • ADCs
      • Spray Dried Dispersions
      • Micronization & Jet Milling
      • Inhaled Delivery (DPI)
    • Locations
      • Bend, Oregon, USA
      • Monteggio, Switzerland
      • Nansha, China
      • Tampa, Florida, USA
      • Visp, Switzerland
    • Knowledge Center
      • Webinars
      • Presentations
      • Publications
      • Meet the Experts
      • View all
    View all Small Molecules offerings
    View all locations
    Clinical drug development & preformulation 

    Knowledge Center

    View all the latest resources


    Visit our Knowledge Center

  • Biologics
    • Modalities
      • Mammalian
      • Microbial
      • ADCs / Bioconjugates
      • Drug Product
    • Technologies & Products
      • Expression Technologies
      • Discovery Products
      • Bioprocessing Products
    • Discovery and Preclinical
      • Early De-risking & Optimization
      • Cell Line & Strain Development
      • Process Development & Optimization
      • Analytical Development
      • Formulation Development
      • Non-GMP Manufacture
    • Clinical and Commercial
      • Process Development & Optimization
      • Formulation Optimization
      • cGMP Drug Substance Manufacture
      • cGMP Drug Product Manufacture
    View all Biologics offerings
    Technical Support
    View all locations
    Regulatory Support
    Slough lab worker at microscope 

    Knowledge Center

    View all the latest resources available on site


    Visit our Knowledge Center

  • Cell & Gene
    • Services
      • Process Development
      • cGMP Manufacturing
      • Regulatory Consulting
      • Bioassay Services
      • Tissue Acquisition
    • By Modality
      • Autologous
      • Allogeneic
      • Viral Vectors
      • iPSCs
      • Exosomes
    • Technologies
      • MODA® Platform
      • Cocoon® Platform
      • Nucleofector® Technology
      • TheraPEAK® Media
    • Knowledge Center
      • Webinars
      • Articles
      • Whitepapers & Publications
      • eBooks
      • Presentations
      • View all
    View all Cell & Gene offerings
    View all Bioscience Products
    View all locations
  • Capsules & Health Ingredients
    • Health Ingredients
    • Nutraceutical capsules
    • Pharmaceutical capsules
    • Capsule filling equipment
  • Contact
Small Molecules
Small Molecules
Services
  • Drug Substance (API)
  • Particle Engineering
  • Drug Product
Technologies
  • Highly Potent API (HPAPI)
  • ADCs
  • Spray Dried Dispersions
  • Micronization & Jet Milling
  • Inhaled Delivery (DPI)
Locations
  • Bend, Oregon, USA
  • Monteggio, Switzerland
  • Nansha, China
  • Tampa, Florida, USA
  • Visp, Switzerland
Knowledge Center
  • Webinars
  • Presentations
  • Publications
  • Meet the Experts
  • View all
Back
Biologics
Biologics
Modalities
  • Mammalian
  • Microbial
  • ADCs / Bioconjugates
  • Drug Product
Technologies & Products
  • Expression Technologies
  • Discovery Products
  • Bioprocessing Products
Discovery and Preclinical
  • Early De-risking & Optimization
  • Cell Line & Strain Development
  • Process Development & Optimization
  • Analytical Development
  • Formulation Development
  • Non-GMP Manufacture
Clinical and Commercial
  • Process Development & Optimization
  • Formulation Optimization
  • cGMP Drug Substance Manufacture
  • cGMP Drug Product Manufacture
Back
Cell & Gene
Cell & Gene
Services
  • Process Development
  • cGMP Manufacturing
  • Regulatory Consulting
  • Bioassay Services
  • Tissue Acquisition
By Modality
  • Autologous
  • Allogeneic
  • Viral Vectors
  • iPSCs
  • Exosomes
Technologies
  • MODA® Platform
  • Cocoon® Platform
  • Nucleofector® Technology
  • TheraPEAK® Media
Knowledge Center
  • Webinars
  • Articles
  • Whitepapers & Publications
  • eBooks
  • Presentations
  • View all
Back
Capsules & Health Ingredients
Capsules & Health Ingredients
Back
Contact
Back
  • Home
  • Biologics
  • Mammalian Biopharmaceutical Services
  • Mammalian Cell Line Development

Cell Line Development

Work with our cell culture teams, to benefit from our advanced technologies and extensive experience, as well as a recognized and stable cell line using our GS Xceed® combined with GS piggyBac® Gene Expression Systems.
Support your cell line development
35+ Years' Experience
800+ Cell Lines Taken to GMP Manufacture
145+ IND/IMPD Filings Supported

A suite of cell line development (CLD) services with your priorities in mind for any molecular format

CLD requires generating single cell-derived clones that produce high and consistent levels of target therapeutic protein.

Once the lead candidate has been identified and a vector generated for use in the selected host cell, the CLD process begins. The process will be tailored to fit the molecule and program needs.

The vector is transfected in a monoclonal host cell line that will not only be able to deliver high titers and desired product characteristics, but also be transferable to manufacturing. At the end of the CLD process, a lead manufacturing cell line will be selected and a research cell bank generated.

The combination of host cell line, vector and stringency of selection enables us to provide our customers with high producing cell lines suited to fit a commercially relevant process.


Advanced technologies used to enhance yield and shorten timelines

Creating cell lines with future manufacturability, cost of goods and speed in mind is of critical importance in today’s biopharmaceutical development.

In addition, there is a large shift in biologics drug development pipelines to newer and more complicated formats. Those next-generation molecules require appropriate expression technologies to realize their potential.

By working with our expert cell culture teams in our Slough (UK), Visp (CH), Guangzhou (China) and Tuas (SG) sites, you will benefit from our advanced technologies and from our GS Gene Expression System® toolbox: including GS Xceed® and GS piggyBac®  to develop a recognized and stable cell line.

Building on more than 35 years' experience, we can support the development and manufacturing of a large variety of molecules ranging from simple monoclonal antibodies to fusion and scaffold proteins.

Our services can be customized to accommodate your priorities in terms of timeline, yield optimization, budget and risk.

Examples of technologies enabling our CLD offering


Transfection: GS piggyBac®

Transposon technology that allows a targeted insertion of the DNA in high-performing regions of the genome. Combining our GS System® with piggyBac™ transposon technology results in increased yields with both pools and clones.


Cloning: Beacon™ Opto-fluidic Technology

Fully enclosed multifluidic platform designed to significantly shorten the cell selection process and bring your molecule into clinical testing faster.


Expansion: GSv™ Platform Process

GSv9 Media and Feeds to unleash the full expression potential of your protein, enhancing product quality

Achieve a seamless transition from development into cGMP manufacturing

Your cell line will be developed using procedures based on achieving high product titers and the desired product characteristics. Selection experiments carried out in miniature bioreactors with an abridged version of our platform manufacturing process will help to reduce risks at later stages and allow a seamless transition from development into cGMP manufacturing.

A close interaction with regulatory authorities worldwide eases regulatory hurdles, since these cell lines will be constructed, cloned, and characterized according to current regulatory guidelines. In addition, the use of electronic notebooks enables real-time data entry, reduces human error, and offers the full traceability required by regulatory authorities. To date, we have successfully supported over 145 IND/IMPD.

A dedicated cGMP unit within our licensed manufacturing facility is used to create master and working cell banks for subsequent manufacturing use. The cell banks are characterized in accordance with FDA and European regulatory agency requirements. For safety and security considerations, dual-site storage of all cell banks is maintained between our facilities.

Related Offering

Ibex® Design | Standard mAbs DNA-to-IND Program
Benefit from our fixed price, fastest DNA-to-IND program that minimizes risk and uncertainty from...
Learn More
Bispecific Antibodies DNA-to-IND Program
We provide an integrated drug substance/drug product DNA to IND program with reliable timelines...
Learn More
Fabs, Fusion, Scaffold and Other Recombinant Proteins DNA-to-IND Program
We will screen more clones to find the highest titer clone. The offering is suitable for customers...
Learn More
Process Development and Optimization
We provide access mammalian cell culture process development, optimization and validation services...
Learn More
Analytical Development
We provide analytical capabilities encompassing a wide range of technologies to support all stages...
Learn More
Drug Substance Manufacturing
Our global biopharmaceutical mammalian manufacturing network offers a range of cGMP production...
Learn More
Parenteral Drug Product Formulation Development
We offer formulation development for all biologics modalities and dosage forms. Learn more.
Learn More
Drug Product Manufacturing
We offer fully integrated biologics manufacturing services from selection and qualification of the...
Learn More
Regulatory Services for Biologics
Partner with our dedicated biologics regulatory team to define the optimal regulatory strategy for...
Learn More
Biologics

Related Insights

Knowledge Center
KC Whitepaper thumbnail
Whitepaper/Executive Summary
How Lonza’s Ibex® Design 2.0 Program Accelerates Time to IND
Speed to clinic and to market is increasingly gaining importance among biopharmaceutical drug...
Presentation (on-demand)
CMC Strategy to take Bispecifics from DNA to IND in 13 Months
Lonza has applied it's 35 years of CMC experience in Biologics to develop an end-to-end...
Article
Small Biotech Success - Pionyr
Alicia Levey and Kiren Khanduja of Pionyr Immunotherapeutics — a San Francisco-based biotech...
KC Whitepaper thumbnail
Whitepaper/Executive Summary
Ensure Your CMC Strategy Aligns With Clinical Path Requirements and Timelines
Drug manufacturers can no longer apply a standardized approach to development and manufacturing,...
Julier pass road in Switzerland
Webinar (on-demand)
De-risk your journey to the clinic: overcome manufacturability, expression and early material...
Join Rebecca Michael, Principal Group Leader, Early Development Services at Lonza Biologics to learn...
Knowledge Center

Latest news

View all Articles
25 Apr 2022
Lonza Early Development Services and Integral Molecular to Offer Complementary Expertise to Enhance...
View Article
25 Apr 2022
Luzhu Biotech Develops Recombinant Herpes Zoster Vaccine and Bispecific Antibody using Lonza’s GS...
View Article
7 Apr 2022
Lonza and Asher Biotherapeutics to Collaborate on Manufacturing AB359, a Cis-Targeted IL-2...
View Article
27 Jan 2022
HaemaLogiX and Lonza Collaborate to Manufacture KappaMab, a Multiple Myeloma Drug Candidate
View Article
19 Jan 2022
Lonza Drug Product Services Participates in the RealHOPE Project to Assess and Improve Protein...
View Article
18 Jan 2022
Lonza Launches bYlok Technology for the Discovery and Design of Bispecific Antibodies
View Article
8 Dec 2021
Doer Biologics signs licensing agreement with Lonza to develop multi-specific biotherapeutics using...
View Article
17 Nov 2021
Lonza and BlueJay Therapeutics Announce Manufacturing Agreement for its Antibody BJT-778 Targeting...
View Article
View all Articles
Ways to Contact
  • Contact Us
  • Regulatory Support
  • Locations
Resources
  • Knowledge Center
  • Meet the Experts
  • California CCPA Notice
  • Transparency in Coverage
Terms & Conditions
  • Terms and Conditions
  • Legal Disclaimer
  • Privacy Policy
  • Sitemap
Lonza.com
  • Company Overview
  • News & Media
  • Investor Relations
  • Sustainability
  • Careers
© 2022 Lonza. All rights reserved.